NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology)

N/A

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameNP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology)
Drug Alias NameNP-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsAXL receptor tyrosine kinase inhibitorsHepatocyte growth factor receptor inhibitors
TargetsVascular endothelial growth factor receptor 2AXL receptor tyrosine kinaseHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursLung NeoplasmsLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShijiazhuang No 4 Pharmaceutical Co LtdNanjing Nadingfei Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Nadingfei Pharmaceutical Technology Co LtdShijiazhuang No 4 Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsLiver NeoplasmsStomach Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A